Differences in Biomarker Expression in GBM Patients with Early Progression After Surgery


Joshua Palmer MD, Jianliang Li MD, Lawrence Kenyon MD, David W. Andrews, MD, Lyndon Kim MD, Jon Glass MD, Maria Werner-Wasik MD, Wenyin Shi MD, PhD


  • Glioblastoma Multiforme (GBM) is locally aggressive
  • GBM is the most common primary brain tumor in adults
  • Surgery followed by temozolomide and radiotherapy are the standard of care
  • Attempts have been made to increase radiation dose, pursue more aggressive chemotherapy, or add targeted therapy
  • Biomarker expression may help individualize treatment decisions

Download Publication